Announcements Trials

Browse Landscape

Phase

Phase 1 5 Phase 1/2 2 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 20 Leukemia, Myeloid, Acute 8 Recurrence 7 Neoplasms, Plasma Cell 4 Lymphoma, Large B-Cell, Diffuse 3 Lymphoma, Extranodal NK-T-Cell 3 Lymphoma 3 Thymoma 2 Ovarian Neoplasms 2 Carcinoma 2 Wilms Tumor 1 Uterine Cervical Neoplasms 1 Triple Negative Breast Neoplasms 1 Smoldering Multiple Myeloma 1 Small Cell Lung Carcinoma 1 Sarcoma, Alveolar Soft Part 1 Sarcoma 1 Richter's Transformation 1 Rhabdoid Tumor 1 Prostatic Neoplasms 1 Oligodendroglioma 1 Neurofibrosarcoma 1 Neoplasms 1 Neoplasm, Residual 1 Myelodysplastic Syndromes 1 Melanoma 1 MDS 1 Lymphoma, T-Cell, Peripheral 1 Lymphoma, T-Cell, Cutaneous 1 Lymphoma, B-Cell 1

Interventions

Doxorubicin 62 Ifosfamide 39 Gemcitabine 29 Radiotherapy 27 Filgrastim 27 Cyclophosphamide 26 Docetaxel 19 Vincristine 18 pembrolizumab 17 Etoposide 17 pazopanib 16 Cisplatin 16 Nivolumab 15 Trabectedin 14 apatinib 13 Magnetic Resonance Spectroscopy 13 Carboplatin 12 Irinotecan 11 Bevacizumab 11 Temozolomide 10 Sirolimus 10 camrelizumab 9 anlotinib 9 Surgical Procedures, Operative 9 Sorafenib 9 Paclitaxel 9 Ipilimumab 9 Injections 9 Dactinomycin 9 Topotecan 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Sarcoma × selinexor × Clear all

NCT06114004 2025-06-25

SeliSarc

Asociación Europea y Latinoamericana SELNET para la Investigación en Sarcomas

Phase 2 Recruiting

Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡